Navigation Links
Gamma Pharmaceuticals, Inc. Completes Sale and Books Revenue with National Pharmacy Chain
Date:6/27/2011

LAS VEGAS, June 27, 2011 /PRNewswire/ -- Gamma Pharmaceuticals, Inc. (NASDAQ: GMPM.PK), a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally, announced today, the Company has completed a sale and revenue collection cycle with a major pharmacy retail chain.  Gamma shipped the Company's energy gel products to a Northeast distribution center for delivery to retail outlets in the New York metropolitan area.  The retail chain has more than 8,000 outlets nationwide.  Gamma's CEO Peter Cunningham noted, "Over the past 2 years, the retail pharmacy sector absorbed the effect of the economic crisis and has started to recover.  With the sector's recovery underway, we have seen renewed interest in Gamma's new technologies and brands nationwide. This interest is paralleled in the supermarket and convenience store channels." He continued, "the credit facility announced in our June 8th 2011 press release will help us fill more orders and address many other retail opportunities."

About Gamma Pharmaceuticals, Inc.

Gamma Pharmaceuticals, Inc., (www.gammapharma.com) is a marketing and product formulation company selling its own branded products through wholesalers and direct to retailers, both in the US and internationally.  Gamma's core focus is the marketing and sale of vitamins and nutriceuticals, OTC pharmaceutical products and personal care products in the United States.  Branded nutritional supplements are sold under the trademarks Brilliant Choice™ nutritional supplements featuring the call to action "You've made a brilliant choice for your nutrition;"  SAVVY™ adult nutritional supplements featuring the call to action, "Be SAVVY Stay Healthy;" and, Gamma Energy Products™ a high performance supplement featuring the call to action, "Get Your Gamma On."  Gamma's customer focus is on selling products in the Lifestyle of Health & Sustainability ("LOHAS") marketplace and in the Energy Supplement Market.  A series of innovative marketing programs supports Gamma's product sales and retail partners.

At present Gamma manufactures in North America, and distributes in the United States.  Gamma's products utilize proprietary "Gel Delivery Technology®", to create innovative gel product forms; that give consumers a more pleasant experience.  Gel Delivery Technology® characteristics include rapid absorption, convenience and taste great.  Market categories Gamma targets are growing as rapidly as 60% per year.  Gamma has developed formulas and strategies for Metabolic Syndrome and Diabetes Type II, Stress Reduction, Cognition, Well being, Menopause Symptoms and Personal Care Products.  Gamma also develops and manufactures house brands for major retailers.  At this time, Gamma has a total of 36 SKU's and holds licenses for 9 SKUs in China.

Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this Press Release regarding any impact the quotation of the Company's stock has on the Pink Sheets or the lack thereof on the OTCBB, and any other effects of the above are forward-looking statements. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: Gamma Pharmaceuticals, Inc.
Joe Cunningham, CFO (jcunningham@gammapharma.com)
Direct:  (651) 204 2048
Office:  (702) 989 5262  


'/>"/>
SOURCE Gamma Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
2. Sugammadex Trials Demonstrate Rapid Recovery from Profound Neuromuscular Blockade During General Anesthesia
3. Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC
4. Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics
5. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
6. Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously
7. Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimers Disease Announced
8. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
11. U.S. FDA Issues Action Letter for Sugammadex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 4, 2016 Research ... "Global Cancer Stem Cell Therapy Market Outlook 2020" ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has improved significantly ... expected to be developed in coming years. Many cancer ... Cancer stem cell therapies are also expected to be ...
(Date:5/3/2016)... , May 3, 2016   BIOTRONIK ... technology, today announced Food and Drug Administration (FDA) ... defibrillator that provides heart failure patients with access ... devices also have remote monitoring with daily automatic ... the heart rate in response to physiological demands. ...
(Date:5/3/2016)... Pharmaceutical giant Johnson & Johnson has been ... says its talc-based powder products caused ovarian cancer. The ... million in compensatory damages and $50 million in punitive ... , This is the second in a ... same court awarded $72 million to the family of ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... Chronic stress can have a silent, yet ... weaken the immune system and increase inflammation, both of which raise the risk of ... congenital heart disease program at Harvard-affiliated Massachusetts General Hospital. Chronic stress also can lead ...
(Date:5/5/2016)... Texas (PRWEB) , ... May 05, 2016 , ... ... relationship-marketing firm, honored finalists and winners Tuesday evening, May 3, at the 2016 ... Texas. , Scott Pettigrew, Vice President and Chief Security Officer of HMS, ...
(Date:5/5/2016)... ... 2016 , ... If you don’t mind a bit of prickly therapy to ... to consider a treatment that some have called the next great tool in dermatology ... also known as skin needling, is a procedure using a device covered with tiny, ...
(Date:5/5/2016)... ... 05, 2016 , ... Pigment Laser Tattoo Removal Center is proud to be ... PiQo4™ laser, the first 4-wavelenth picosecond laser to receive FDA Clearance. This new ... on the market. Jeremy Miller, Tattoo Artist and former reality show contestant on ...
(Date:5/5/2016)... ... May 05, 2016 , ... Liposuction specialist Marcia V. Byrd, MD spoke ... Missouri at the Marriot St. Louis Airport Hotel. This year’s conference was titled “Living ... conference about her unique specialization in treating Lipedema. Dr. Byrd is considered one of ...
Breaking Medicine News(10 mins):